The FIRST AND ONLY Tdap\(^a\) vaccine approved for repeat vaccination\(^1\)

- Adacel vaccine is approved for repeat vaccination 8 years or more after the initial dose\(^1\)
- Immunity acquired from vaccination can wane—so help maintain pertussis protection with a second dose\(^2\)
- Adacel vaccine is the first and only Tdap vaccine in a prefilled syringe manufactured without natural rubber latex\(^1\)
- After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise\(^1\)

INDICATION FOR ADACEL VACCINE

Adacel vaccine is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

Please click here to see full Important Safety Information.

Please see the full Prescribing Information.
INDICATION FOR ADACEL VACCINE

Adacel vaccine is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

IMPORTANT SAFETY INFORMATION FOR ADACEL VACCINE

Adacel vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause.

For one presentation of Adacel, the tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals. The vial stopper is not made with natural rubber latex.

If Guillain-Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid-containing vaccine, if progressive or unstable neurologic disorders exist, or if adverse events have occurred in temporal relation to receipt of pertussis antigen-containing vaccine, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.

Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid-containing vaccine.

Syncope (fainting) can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

Please see the full Prescribing Information.


CPT® Code: 90715

*CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

Adacel vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.